Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ACETAMINOPHEN\ORPHENADRINE: 59 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
59
Total FAERS Reports
2 (3.4%)
Deaths Reported
15
Hospitalizations
59
As Primary/Secondary Suspect
2
Life-Threatening
2
Disabilities

Active Ingredient: ACETAMINOPHEN\ORPHENADRINE CITRATE ·

First Report: 19850101 · Latest Report: 20250827

What Are the Most Common ACETAMINOPHEN\ORPHENADRINE Side Effects?

#1 Most Reported
Drug dependence
16 reports (27.1%)
#2 Most Reported
Overdose
12 reports (20.3%)
#3 Most Reported
Somnolence
10 reports (16.9%)

All ACETAMINOPHEN\ORPHENADRINE Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Drug dependence 16 27.1% 2 2
Overdose 12 20.3% 2 2
Somnolence 10 17.0% 0 5
Asthma 7 11.9% 0 0
Dependence 7 11.9% 0 0
Hypokalaemia 7 11.9% 0 7
Hypoacusis 6 10.2% 0 0
Osteoporosis 6 10.2% 0 0
Skin cancer 6 10.2% 0 0
Back injury 5 8.5% 0 0
Choking 5 8.5% 0 0
Delusion 5 8.5% 0 0
Fall 5 8.5% 0 0
Hyperhidrosis 5 8.5% 0 0
Hypopnoea 5 8.5% 0 0
Intentional overdose 5 8.5% 0 5
Learning disability 5 8.5% 0 0
Metabolic acidosis 5 8.5% 0 5
Myocardial infarction 5 8.5% 0 0
Somnambulism 5 8.5% 0 0

Who Reports ACETAMINOPHEN\ORPHENADRINE Side Effects? Age & Gender Data

Gender: 54.7% female, 45.3% male. Average age: 49.8 years. Most reports from: CA. View detailed demographics →

Is ACETAMINOPHEN\ORPHENADRINE Getting Safer? Reports by Year

YearReportsDeathsHosp.
2007 1 0 1
2011 1 0 1
2015 3 0 0
2017 2 0 0
2018 1 1 0
2021 1 0 1
2022 4 0 1
2023 3 0 1
2024 1 0 1
2025 1 0 0

View full timeline →

What Is ACETAMINOPHEN\ORPHENADRINE Used For?

IndicationReports
Product used for unknown indication 44

Official FDA Label for ACETAMINOPHEN\ORPHENADRINE

Official prescribing information from the FDA-approved drug label.